



Biosimilars Latam - Brazil 2021

25th - 26th August
Online Forum

Portuguese - English
Simultaneous Translation

Sponsors



Supporters

Media Partners

Speaker Panel



Tiago Rocca
Instituto Butantan, Brazil
Strategic Partnerships and Business
Development Manager

Chairman



Elkiane Macedo Rama
ANVISA, Brazil
Health Regulation Expert



Andrea Padovani
ANMAT, Argentina
Head of the Pharmacological Clinical Evaluation
Service of the Directorate of Evaluation and Control
of Biological Products and Radiopharmaceuticals



Roberto Frontini
EMA, Germany
Pharmacovigilance Risk Assessment
Committee (PRAC) alternate member



Gustavo Mendes Lima Santos
ICH / ANVISA, Brazil
ICH MC Member, General Manager of
Medicines and Biological Products



Shahin Kauser
MHRA, United Kingdom
Leading Senior Scientific Assessor



Luciana Rahal Abrahão
Brazil
Independent Medical Affairs Professional



Cristina Ausin
FDA, USA
Scientific Reviewer



Thiago Mares Guia
Bionovis, Brazil
Scientific & Business Executive Director



Philippe Lauwers
Terumo, Belgium
Director Technology Development



Julie Marechal-Jamil
Medicines for Europe, Belgium
Director Biosimilars Policy & Science



Gloria Giraldo
Health Canada, Canada
Senior Scientific Evaluator



Edilson Uiechi
Bionovis, Brazil
Institutional Affairs & Business
Development Manager



Mauricio Ede-Filho
Sandoz, Canada
Chief Medical & Scientific Officer

Speaker Panel



Dorthe Bartels
AMGROS, Denmark
Senior Strategic Advisor, Negotiator
and Head of the Biosimilar task force



Nicolas Estrada
Merck, Mexico
Single-Use customer applications



Marcos Roman Calgaro
Thermo Fisher Scientific, Brazil
Sr. Manager – LATAM, Bioproduction Group



Monique Samaan
Cristalia, Brazil
Senior Biotechnology R&D Scientist



Kattia Milena Riaño
Sandoz, Colombia
Regulatory Affairs Manager




Tore K. Kvien
University of Oslo, Norway
Diakonhjemmet Hospital, Oslo, Norway
Professor em/Senior Research Advisor



Fernando Carmona
Cytiva, Argentina
Upstream Technical Sales Specialist



Natalia Sousa Freitas Queiroz
University of Sao Paulo School of Medicine, Brazil
Gastroenterology Sciences
Postgraduate Program Professor



Mariana Peixoto
Sociedade Mineira de Reumatologia, Brazil
President Sociedade Mineira
de Reumatologia



Rodrigo Oliveira
bioMérieux, Brazil
Field Application Specialist, Healthcare



Daniel Morales
University of Dundee, United Kingdom
Epidemiologist and Academic GP



Brian Godman
University of Strathclyde, UK and Sefako
Makgatho Health Sciences University, South Africa
Professor

Chairman



Tiago Rocca
Instituto Butantan, Brazil
Strategic Partnerships and Business
Development Manager

Br 09:00 Opening Ceremony

Br 09:10 Regulatory Update



Elkiane Macedo Rama
ANVISA, Brazil
Health Regulation Expert

Br 09:50 Quality Control Challenges for Biologics
Production



Monique Samaan
Cristalia, Brazil
Senior Biotechnology R&D Scientist

Br 10:25 Pathway to Overcome Primary Packaging
and Drug Product Manufacturing Challenges -
Case Study of Ophthalmic Drug



Philippe Lauwers
Terumo, Belgium
Director Technology Development

Br 10:55 Networking Break

Br 11:25 Biosimilars Prescription for Rheumatic
Diseases



Mariana Peixoto
Sociedade Mineira de Reumatologia, Brazil
President Sociedade Mineira de
Reumatologia

Br 11:55 Scalability in mAb's Production



Fernando Carmona
Cytiva, Argentina
Upstream Technical Sales Specialist

Br 12:25 Pharmacovigilance Challenges for
Biosimilars



Roberto Frontini
EMA, Germany
Pharmacovigilance Risk Assessment
Committee (PRAC) alternate member



Shahin Kausar
MHRA, United Kingdom
Leading Senior Scientific Assessor




Andrea Padovani
ANMAT, Argentina
Head of the Pharmacological Clinical Evaluation
Service of the Directorate of Evaluation and Control
of Biological Products and Radiopharmaceuticals

Moderator



Julie Marechal-Jamil
Medicines for Europe, Belgium
Director Biosimilars Policy & Science



Br 13:10 Lunch Break

Br 14:10 Challenges in Tech Transfer for Biosimilars
in Brazil



Tiago Rocca
Instituto Butantan, Brazil
Strategic Partnerships and Business
Development Manager

Br 14:40 Biosimilars International Regulatory
Framework: Canada's Review



Gloria Giraldo
Health Canada, Canada
Senior Scientific Evaluator

Br 15:10 Q&A/Open Mic and Wrap up

Chairman



Tiago Rocca
Instituto Butantan, Brazil
Strategic Partnerships and Business
Development Manager

Br 09:00 Summary 1st Day

Br 09:10 Biosimilars Safety



Daniel Morales
University of Dundee, United Kingdom
Epidemiologist and Academic GP

Br 09:40 Partnerships for Productive Development and their Contribution to Brazil's Health Care System



Edilson Uiechi
Bionovis, Brazil
Institutional Affairs & Business
Development Manager

Br 10:10 Rapid Sterility Testing to Ensure Patient Safety



Rodrigo Oliveira
bioMérieux, Brazil
Field Application Specialist, Healthcare

Br 10:40 Networking Break

Br 11:10 Biosimilars Regulatory Licensing Framework



Cristina Ausin
FDA, USA
Scientific Reviewer



Mauricio Ede-Filho
Sandoz, Canada
Chief Medical & Scientific Officer

Moderator



Gustavo Mendes Lima Santos
ICH / ANVISA, Brazil
ICH MC Member, General Manager of
Medicines and Biological Products

Br 11:55 Modern Technical Solutions for Biosimilars



Marcos Roman Calgare
Thermo Fisher Scientific, Brazil
Sr. Manager – LATAM, Bioproduction
Group



Nicolas Estrada
Merck, Mexico
Single-Use customer applications

Moderator



Tiago Rocca
Instituto Butantan, Brazil
Strategic Partnerships and Business
Development Manager

Br 12:40 Success Stories Surrounding Biosimilars



Dorthe Bartels
AMGROS, Denmark
Senior Strategic Advisor, Negotiator and
Head of the Biosimilar task force



Thiago Mares Guia
Bionovis, Brazil
Scientific & Business Executive Director

Moderator



Brian Godman
University of Strathclyde, UK and Sefako Makgatho
Health Sciences University, South Africa
Professor

Br 13:25 Lunch Break

Br 14:25 Originator and Biosimilar Market Dynamics



Brian Godman
University of Strathclyde, UK and Sefako Makgatho
Health Sciences University, South Africa
Professor

Br 14:55 Manufacturing Biosimilars: Production Process Improvement and Hurdles to be Faced



Kattia Milena Riaño
Sandoz, Colombia
Regulatory Affairs Manager

Br 15:25 Upcoming Considerations for Biosimilars



Tore K. Kvien
University of Oslo, Norway
Diakonhjemmet Hospital, Oslo, Norway
Professor em/Senior Research Advisor



Luciana Rahal Abrahão
Brazil
Independent Medical Affairs Professional

Moderator



Natalia Sousa Freitas Queiroz
University of Sao Paulo School of Medicine, Brazil
Gastroenterology Sciences Postgraduate
Program Professor

Br 16:10 Closing Words by the Chairman

Carefully Crafted



K-Pack® II

Hypodermic needles designed for the pharmaceutical industry

- Color-coded and tamper-evident label for easy identification
- Ultra-sharp needles for decreased penetration resistance¹
- Broad portfolio of sizes and lengths available

Check out our innovative developments for K-Pack II needle with Ultra Thin Wall technology!

www.terumo-ps.com

Please note that some items may not be available in all regions, check with your local Terumo Pharmaceutical Solutions contact for details.
¹ Data on file.

PM-01248

Our Quality, Your success



Helping to sustain therapeutic success with patients worldwide, Terumo Pharmaceutical Solutions offers comprehensive injectable drug packaging and delivery solutions to pharmaceutical and medical device manufacturers around the world. Technology for today and tomorrow.

Think Terumo.

P1M-04044

www.terumo-ps.com

 **TERUMO** PHARMACEUTICAL
SOLUTIONS

info@jackleckerman.com | www.jackleckerman.com

JackLeckerman 
GLOBAL HUMAN INTERACTION

Evolve with flexibility

Single-use bioprocessing



Single-use portfolio across the bioprocess spectrum



Fluid management
ReadyToProcess filtration devices | ReadyCircuit bags and tubing assemblies | ReadyMate aseptic connectors



SARTORIUS


Soluções ricas em informações para transformar a descoberta de produtos biológicos

O Sistema de **Live cell analysis Incucyte®** e as **plataformas de análise de células de citometria de fluxo avançadas Intellicyt® iQue** da Sartorius oferecem soluções exclusivas de alta capacidade para rastrear processos biológicos complexos e gerar dados mais profundos e biologicamente relevantes para caracterizar fenótipo, ativação e função.

Saiba mais em: sartorius.com/biologics

E-mail: latam.marcom@sartorius.com

Simplifying Progress



FASTER MICRO TESTING. BETTER PRODUCTIVITY.



©2020 bioMérieux, Inc. • BIOMÉRIEUX and the BIOMÉRIEUX logo are used pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies

Rapid answers from in-process controls confirm your production is operating effectively and efficiently — thus ensuring product safety and quality while improving productivity. Protect your process, stay in compliance, and improve your bottom line with a comprehensive testing solution.

BACT/ALERT® 3D DUAL-T®

The automated sterility testing solution that's making compendial methods a thing of the past.



SCANRDI®

The phase cytometry system for filterable products that delivers answers in just four hours.



Learn more at www.biomerieux-industry.com

PIONEERING DIAGNOSTICS
biomerieux-industry.com

Biographies



Tiago Rocca
Instituto Butantan, Brazil

Mr. Rocca serves as Strategic Partnerships & Business Development Manager at Instituto Butantan. Rocca has been working at Butantan for over 14 years and has assumed responsibilities in several other areas related to vaccines and biopharmaceuticals production, Technology Transfer, Validation, Quality Assurance and Compliance. Pharmacist and post-graduated in Health Law at Public Health School of University of São Paulo and in Pharma Business Management at Higher School of Advertising and Marketing (ESPM). Currently is the Secretary of Emerging Biopharmaceuticals Manufacturers Network (EBPMN) and a member of Executive Committee of Developing Countries Vaccine Manufacturers (DCVMN).



Elkiane Macedo Rama
ANVISA, Brazil

Elkiane is a Health Regulation Expert at the Biological Products Office of the Brazilian Health Regulatory Agency - ANVISA. She has been working for 16 years as a reviewer of Anvisa, and the last 7 years reviewing both CMC and clinical trials dossiers of biological and biotechnological products, including biosimilars. She has been a member of ICH Q12 Expert Working Group. She holds a Pharmacy and Biochemistry Degree with specialty in Pharmaceutical Industry (2004), a Master's degree in Toxicology (2013), a Postgraduate certificate in Toxicology (2009), and a Postgraduate certificate in Health Regulation (2007).



Monique Samaan
Cristalia, Brazil


Monique is a Senior Biotechnology R&D Scientist at Cristália Prod. Químicos Farmacêuticos in Brazil. She has a cross-functional experience from API to drug product, focusing on development, optimization and scale-up for both early and late-stage biologics. She has been part of Cristalia's team for 10 years and participated intensively in preparing CMC Module 3 and Comparability

Exercise for Criscy® register in ANVISA, the first biosimilar growth hormone 100% developed and manufactured in Brazil.




Philippe Lauwers
Terumo, Belgium

Philippe Lauwers is Director Technology Development at Terumo Pharmaceutical Solutions (TPS). Philippe graduated in Biotechnology from Ghent University, Belgium, and worked as a scientific researcher at the Catholic University of Leuven, Belgium. Upon obtaining an additional degree in Biomedical Engineering, he moved from an academic to an industrial environment. He has been active in the medical device and pharmaceutical packaging sector for the last ten years.



Mariana Peixoto
Sociedade Mineira de Reumatologia, Brazil

President Sociedade Mineira de Reumatologia



Fernando Carmona
Cytiva, Argentina

I'm a Biotechnologist who made his studies at the University of San Martin in Argentina and my thesis was based on cell adhesion. I began my professional career serving as a scientific assessor. Then my career followed in the human and animal pharmaceutical industry in cell culture area, protein purification and process development. I was able to acquire knowledge about equipment and application techniques. This previous works allowed me to understand the whole biotechnology flow path which now I'm using in my daily work on Cytiva



Roberto Frontini
EMA, Germany

Roberto Frontini was born in Milan (Italy) 1950. He moved to Germany 1969 and studied music in Frankfurt/Main. He was from 1976 to 1981 resident conductor at the theatre of Lübeck and 1978 to 2002 chief conductor of the Youth Symphony Orchestra Lübeck.

He studied Pharmacy in Hamburg from 1983 to 1988 and he obtained the PhD 1993. After working as hospital pharmacist in Lübeck and Cologne he was 2001 to 2017 Director of Pharmacy, Qualified Person and lecturer on Pharmacoepidemiology at the University Hospital of Leipzig as well as Director for Patient Care at the Centre for Patient Safety. From 2015 to 2017 he was board member and 2009 to 2015 president of the European Association of Hospital Pharmacists (EAHP). Since June 2019 is alternate member of the Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicine Agency (EMA) in Amsterdam.



Shahin Kauser
MHRA, United Kingdom

Shahin is a Leading Senior Scientific Assessor and joined the Medicines and Healthcare products regulatory (MHRA) Agency (former MCA) in 2001. She has extensive experience of the 'life-cycle' of pharmacovigilance both nationally and in Europe. Her current portfolio includes monitoring the post-marketing safety of medicines in various therapeutic areas including biosimilars (such as epoetins), G-CSFs, blood disorders, multiple myeloma and malignant melanoma. Shahin has expertise in assessing risk management plans, additional risk minimisation measures and assessing their effectiveness. She also has experience of conducting benefit-risk assessment, EAMS, PSURs, safety variations and renewal procedures.



Andrea Padovani
ANMAT, Argentina

Head of the Pharmacological Clinical Evaluation Service of the Directorate of Evaluation and Control of Biological Products and Radiopharmaceuticals Doctor graduated from the University of Buenos Aires, adjunct professor of the Department of Medicine Orientation Infectology, U.D.H Hospital de Clínicas. She completed the basic residency in the Medical Clinic at the Penna General Hospital of Agudos and her post-basic residency in Infectology at the Hospital de Infectious F.J. Muñiz. She is technical-scientific evaluator of ANMAT Clinical Trials since 1999.



Julie Marechal-Jamil
Medicines for Europe, Belgium

Leading the Biosimilar Medicines Group, a sector group of Medicines for Europe, Julie aims at creating and nurturing dialogue with experts and partners across healthcare systems. The main objectives of the Biosimilar Medicines Group are to support and facilitate the design, evolution and implementation of policies aimed at fostering greater access to biologic therapies and other healthcare products and services, with biosimilar medicines use as catalyst for smart investment in health. Since January 2019 on, she has been co-chair of the Biosimilars committee of the International Generic and Biosimilar medicines Association (IGBA) focusing on convergence of global policies and standards.



Gloria Giraldo
Health Canada, Canada

Dr. Gloria Giraldo is a Microbiologist, Master in Epidemiology from the University of Antioquia, Colombia; a Nurse Specialist in Oncology, from the University of Buffalo, U.S.A; Specialist in Burden of the Disease from the University of Harvard, U.S.A. Dr. Giraldo has international experience in oncology research, epidemiology of infectious diseases, pharmacoepidemiology and pharmacovigilance. Currently, she is a Senior Scientific Evaluator at the Marketed Health Products Directorate of Health Canada in Ottawa, Canada.

Dr. Giraldo has experience coordinating and conducting clinical trials, including analysis of quality of life; in pharmacoepidemiology, and in pharmacovigilance of commercialized products, including the evaluation of risk management plans; the application of methodologies for risk-benefit assessment and in the application of methods for health research and risk communication. Currently, Dr. Giraldo works mainly in the pharmacovigilance of vaccines, rare diseases, and vaccines/therapies related to COVID-19, and provides technical support to the Pharmacovigilance Network of the Pan American Health Organization, the Uppsala Monitoring Center (UMC) and the International Society of Pharmacovigilance (ISoP) and serves as a member of the WHO's Expert Advisory Panel on Medicine Safety.



Daniel Morales
University of Dundee, UK

Dr Morales is an Academic GP and Epidemiologist holding a Wellcome Trust Clinical Research Career Development Fellowship. He is based at the University of Dundee and has a second affiliation with

the University of Southern Denmark. His interests lie in chronic disease epidemiology, drug safety and medicines regulation. He is a current member of the European Medicine Agency Pharmacovigilance Risk Assessment Committee and Emergency Pandemic Task Force.




Edilson Uiechi
Bionovis, Brazil

Institutional Affairs & Business

Development Manager

Experienced Government Affairs with a demonstrated history of working in the pharmaceuticals industry. Skilled in Pharmaceuticals, Governmental Affairs, Vaccines, Oncology, and Haematology. Strong professional with a PhD scholarship focused on Human Reproduction Science from Universidade Federal de São Paulo.



Rodrigo Oliveira
bioMérieux, Brazil

As Pharmacist and Biochemist with a

Master's Degree in Microbiology.

He has 14 years of experience in quality in the pharmaceutical industry in the segments of bioproduction, sterile and non-sterile products. Volunteer and speaker at PDA Brazil and other institutions, always addressing quality issues and new technologies harmonized with international regulatory standards. He is currently an Application Specialist at bioMérieux Brazil.



Cristina Ausin
FDA, USA

Cristina Ausin received her Bachelor's in chemistry and her Masters in chemical engineering from University Ramon Llull in Spain and her Ph.D. in chemistry from the University of Barcelona in Spain. She arrived to the Office of Biotechnology Products in the Food and Drug Administration (FDA) as a post-doctoral fellow in 2004 and spent four years doing research in the oligonucleotide synthesis field. In 2008 she became a researcher reviewer, a full-time reviewer in 2013, and a team lead in 2015. Dr. Ausin joined the Office of Therapeutic Biologics and Biosimilars (OTBB) in FDA in 2018 as a scientific reviewer.



Mauricio Ede-Filho
Sandoz, Canada

Industry professional with nearly 20 years of experience in Clinical Development and Scientific Support to technology, drug and device development at a Global level. I have formal training in Cardiovascular Surgery and Physiology and have worked for large and small organizations. Currently I lead the Scientific Affairs Team at Sandoz Canada, where I have oversight of Regulatory Affairs and the Regulatory Compliance Centre, Medical Affairs, Government Relations & Policy, Patient Support Programs and Medical Information.



Gustavo Mendes Lima Santos
ICH / ANVISA, Brazil

Gustavo Mendes Lima Santos. General Manager of Medicines and Biological Products. Graduated in Industrial Pharmacy from the University of São Paulo (2001), Specialization in Sanitary Surveillance from FIOCRUZ (2007) and Master's Degree in Toxicology Applied to Sanitary Surveillance from the State University of Londrina (2013). Experience of 18 years at Anvisa working in bioequivalence, marketing authorization and clinical research of medicines.



Marcos Roman Calgaro
Thermo Fisher Scientific, Brazil

Education: Ph.D. in Sciences – University of São Paulo, (IFSC), São Carlos, SP-Brazil. (2002-2007)

Master Degree in Genetics and Evolution- Federal University of São Carlos, São Carlos, SP-Brazil. (2000-2002)

B.S. in Genetics – University of Misiones, Posadas, Misiones-Argentina. (1993-1999)

Professional Experience: 2005-2008 Manufacturing Supervisor - Invitrogen do Brasil. São Paulo, SP, Brasil

2008-2015 Bioprocess Product Specialist LATAM - GE Healthcare Life Sciences do Brasil, SP, Brasil

2015 - 2019 Bioproduction Business Development Manager – Brasil - Thermo Fisher Scientific

2019 - now Sr. Commercial Manager LATAM, Bioproduction Group - Thermo Fisher Scientific

Main goal is to develop the Upstream/Downstream Market in LATAM

Focus on Single Use Technology, SU Bioreactors, SUB Mixers, Cell Culture Media GIBCO, Chromatography Media POROS, Analytical Systems



Nicolas Estrada
Merck, Mexico

Nicolás Estrada joined Merck Millipore in 2016 as a Single-Use Sales Development Specialist LATAM. He has worked for more than 15 years in the pharmaceutical industry and has extensive experience in the management of injection product manufacturing areas (aseptic processes). In the commercial and technical approach, he has more than 15 years of experience in filtration and Single-Use technologies. Nicolás received his bachelor's degree as a Bachelor of Pharmaceutical Chemical Biologist from the Autonomous Metropolitan University in Mexico City. He is currently one of the main references of the application, use and implementation of Single-Use technologies in the industry.



Dorte Bartels
AMGROS, Denmark

Senior Strategic Advisor, Negotiator and Head of the Biosimilar task force



Thiago Mares Guia
Bionovis, Brazil

Current position: Scientific & Business Executive Director @ Bionovis, a company focused in developing, manufacturing and marketing biopharmaceuticals, including Biosimilars and innovative Biologics. Physician with 20+ years' experience in Biotechnology RD&I (Academia / Industry) and Translational Medicine/ Research. PhD in Biochemistry and Immunology, Postdoc in Biotechnology and Cell Therapy.



Brian Godman
University of Strathclyde, UK and Sefako Makgatho Health Sciences University, South Africa

Since 2006, Brian has been working with health authorities, their advisors, and academics across countries to

enhance the rational use of medicines and prescribing efficiency. Initially this was across Europe, but now expanded to all continents including South America. This includes both new and established medicines including biosimilars. This has resulted in over 350 papers in peer-reviewed journals since 2008 including multiple papers in South America including both infectious and non-infectious diseases as well as exploring managed entry agreements, access to pharmaceuticals, drug shortages and divestment processes. He has also published extensively on biosimilars across countries.



Kattia Milena Riaño
Sandoz, Colombia

Student of Msc – EU Regulatory Affairs, Marketing Management Specialist Pharmacist. With more than ten (10) years of professional experience, in areas such as: Regulatory Affairs, Quality Assurance and R&D; eight (8) out of ten (10) fully dedicated to the Regulatory Affairs' field. With experience within the Pharmaceutical Industry and in Regulatory Affairs counselling for companies that belong to different sectors. Currently working for the Regulatory Affairs department in a company that belong to Biopharmaceutical sector and recognized as a leader in the commercialization of Biosimilars.



Tore K. Kvien
University of Oslo, Norway
Diakonhjemmet Hospital, Oslo, Norway

Tore K. Kvien has been Professor of Rheumatology at the University of Oslo since 1997 (now professor em) and Head of the Department of Rheumatology at Diakonhjemmet Hospital, Oslo from 1994 to 2019. He was the principal investigator of the Norwegian government-funded NOR-SWITCH trial, which was published in Lancet 2017. He has published more than 600 original research articles, was President of EULAR 2005-2007, Editor-in-Chief of the Annals of the Rheumatic Diseases 2008-2017. He has received several international awards and the Norwegian King in 2019 appointed professor Kvien as Officer First Class of the Royal Order of St Olav.



Luciana Rahal Abrahão

Sandoz, Brazil

Physician, specialist in Internal Medicine and Critical Care, PhD in Health Sciences By USP Medical School. Medical manager in Sandoz Brazil, responsible for Biosimilars.



Natália Sousa Freitas Queiroz

**University of Sao Paulo School of
Medicine, Brazil**

Natália Sousa Freitas Queiroz is Associate Professor of the Gastroenterology Postgraduate Program of the University of Sao Paulo. She completed her Fellowship in Gastroenterology at the Clinics Hospital from the University of Sao Paulo (2012) and achieved her PhD degree in the University of Sao Paulo in 2018. Dr. Queiroz actively participates as a member of the board of coordinators of the Brazilian IBD study group (GEDIIB) and is currently associate editor of Crohn's and Colitis 360 Journal.